Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients

Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients

Mar 22, 2014
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-reports-new-phase-iii-data-showing-secukinumab-ain457-improved-moderate-severe-plaque-psoriasis-patients-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-reports-new-phase-iii-data-showing-secukinumab-ain457-improved-moderate-severe-plaque-psoriasis-patients-0